Introduction
Over a broad range of mammalian species, including the mouse and human, the total cholesterol concentration across all organs averages about 2 mg per gram wet weight of tissue [1, 2] . The proportion of cholesterol throughout the body that is esterified is quite small even though in the plasma and organs like the adrenal glands the bulk of the cholesterol is esterified [3, 4] . Most of the cholesterol in exogenous sources is unesterified [5] . Even if this were not the case, little, if any, of the EC present in tissues originates from dietary intake because pancreatic cholesterol esterase hydrolyzes the EC present in foodstuffs [5] . Thus, the EC distributed throughout the body is generated from three esterifying enzymes, one of which is sterol O-acyltransferase 1 (SOAT1) present in steroidogenic tissues, kidneys, sebaceous glands and macrophages [6, 7] . Another enzyme is SOAT2 (sterol O-acyltransferase 2, or ACAT2) which is expressed in hepatocytes and enterocytes [8] [9] [10] . The role of SOAT2 in generating EC that is incorporated directly into atherogenic lipoproteins has made it an attractive target in dyslipidemia management and prevention [11] . In the plasma compartment, cholesterol esterification is facilitated by lecithin cholesterol acyltransferase (LCAT) [12] . Loss of LCAT function results in a precipitous fall in circulating cholesterol levels, particularly in high density lipoproteins (HDL) [13, 14] .
Tissue EC levels are elevated in a number of rare diseases [3] including Tangier disease [15] , Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD) [16, 17] . These latter disorders result from mutations in LIPA, the gene that encodes lysosomal acid lipase (LAL) [18] . This enzyme hydrolyzes EC and triacylglycerol contained in various types of lipoproteins cleared from the circulation by receptormediated and bulk-phase endocytosis [19, 20] . WD is a severe, earlyonset illness caused by complete loss of LAL activity and typically leads to death in infancy, whereas CESD is a milder, later onset disease in which some residual LAL activity remains. A spontaneous rat model for WD [21] , and a genetically engineered mouse model for CESD, have been invaluable in characterizing the biochemical, histological and molecular changes resulting from a disruption of LAL function [22, 23] , and in evaluating an enzyme replacement therapy for LAL deficiency [24, 25] . Sebelipase alfa is now approved for the treatment of adult and pediatric patients with this rare disorder [26, 27] .
The exceptionally high level of sequestration of EC in the liver in LAL deficiency reflects the fact that this organ is not only the major site of clearance of LDL and very low density lipoprotein remnants (VLDLr), all of which contain appreciable amounts of EC, but it also receives essentially all of the cholesterol that is absorbed from the small intestine, 70-80% of which is esterified [28, 29] . Therefore, one of our first attempts to manipulate hepatic EC sequestration rates in LAL-knockout mice was to give them ezetimibe, a potent intestinal sterol absorption inhibitor, in their diet from the time of weaning until early adulthood. This manipulation culminated in a surprising degree of contraction in whole liver cholesterol content that reflected the combined effects of a reduction in both liver mass and EC concentration [30] . These findings prompted further studies in which we explored how genetic deletion or pharmacological suppression of SOAT2 in LAL-deficient mice impacted the level of disease severity in early adulthood [31, 32] . The remarkable benefit that accrued from both strategies underscored the need to now determine whether the benefits of SOAT2 suppression in LAL deficiency were gender independent and prevailed with age.
Materials and methods

Animals and diets
The progeny were retained to replenish the breeding colony. The genotypes of the mice were determined at or before weaning at 21 or 22 days. All mice were weaned onto a low-cholesterol, low-fat, cereal-based rodent chow diet which they received ad libitum [23] . They were group housed in a light-cycled room and were studied in the fed state towards the end of the dark phase of the lighting cycle. With the exception of one experiment involving milk collection from the stomachs of 7-day old pups, the age of the mice at study ranged from 22 to 120 days. This research was conducted in full conformity with the PHS Policy on Humane Care and Use of Laboratory Animals. All experiments were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center.
2.2.
Quantitation of esterified and unesterified cholesterol in liver and small intestine, of total cholesterol in plasma and whole animal, and of triacylglycerol in liver The mice were weighed, anesthetized, and exsanguinated from the lower vena cava into a heparinized syringe. Depending on their gender and age, the liver and small intestine were excised, rinsed, blotted on filter paper, and weighed. Aliquots of liver from multiple lobes and the entire small intestine were added directly to ∼40 ml of chloroform: methanol (2:1 v/v) for later measurement of the concentrations of unesterified and esterified cholesterol, and, in the case of the liver, triacylglycerol as well. None of the tissue aliquots or whole intestines intended for the measurement of the esterified and unesterified fractions were placed in liquid nitrogen before being added to chloroform: methanol because this can result in an error in the ratio of esterified to unesterified cholesterol [33] . In the study involving 52-day old male mice, the residual carcass was weighed and added to ∼150 ml of alcoholic KOH for subsequent measurement of total cholesterol content. Plasma from the 52-day old male mice was used for the determination of the total cholesterol concentration. For both the 52-and 100-day male old mice, and the 52-and 120-day old female mice, aliquots of chilled plasma were sent immediately to a commercial laboratory for measurement of ALT and AST activities. To determine the proportion of cholesterol in the milk consumed by suckling pups that was esterified, the solidified milk in the stomachs of five 7-day old mice from different litters was harvested, weighed, and placed in chloroform: methanol (2:1 v/v).
The methods for the extraction, separation and quantitation of the esterified and unesterified cholesterol fractions using column and gas chromatography have been described in detail elsewhere [34] , as have the techniques for determining hepatic triacylglycerol content [35] , the plasma cholesterol concentration and whole body cholesterol content [36] . Plasma lipoprotein composition was not determined. The amount of EC, UC or triacylglycerol in tissue was expressed as either mg/g wet weight of tissue, or/and mg per whole organ. Plasma total cholesterol concentrations were expressed as mg/dl, and plasma transaminase activities as units/L. Whole body cholesterol content was expressed as mg/100 g body weight. No tissues were taken for histology.
Relative mRNA expression analysis
In the study with the 52-day old male mice, an aliquot of liver, taken from the core of the largest lobe immediately after the organ had been weighed, was frozen in liquid nitrogen. mRNA levels were measured by qPCR using a Bio-Rad CFX384 Real-Time PCR Detection System. The primer sequences used to measure the mRNA levels for four genes that serve as markers of either macrophage presence (Soat1) (sterol Oacyltransferase 1), or inflammation Mip1α (chemokine (c-c motif) ligand 3), CD11c (integrin alpha x), and Tnfα (tumor necrosis factor alpha) are given in an earlier publication [23] . All analyses were determined by the comparative cycle number at threshold method [37] . The mRNA levels were normalized to cyclophilin, and the values for each mouse were then expressed relative to that obtained for the matching Lal +/+ : Soat2 +/+ controls, which, in each case, was arbitrarily set at 1.0.
Analysis of data
Values are the mean ± SEM for the specified number of animals. GraphPad Prism 6.02 software (GraphPad, San Diego) was used for all statistical analyses. Differences between mean values were tested for statistical significance (p < .05) by either a one-way analysis of variance (ANOVA) or a two-way ANOVA with genotype and age as variables and applying Tukey's multiple comparison test. One objective of these new studies was to investigate whether the impressive benefit of SOAT2 deficiency seen in male LAL knockout mice in early adulthood [31] persisted with age. It was also important to compare liver mass and esterified cholesterol (EC) concentrations in the DKO mice and their Lal −/− : Soat2 +/+ littermates at the time of weaning, given that during at least the first two weeks after birth, mouse pups consume only milk. Earlier studies showed that, at 10 days of age, their milk intake was 0.96 ml per day [38] , and also that mouse milk had a total lipid content of 41.6% and a total cholesterol concentration of 36.9 mg/dl [39] . In milk harvested from the stomachs of 7-day old pups in the current studies, 25 ± 6% was esterified. Hence, in that period of rapid organ development, the intake of cholesterol and lipids by mice generally is far higher than is the case when they are weaned onto a conventional rodent chow diet. At 22 days of age, there was a trend (p > 0.05) toward less hepatomegaly in the Lal
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− mice compared to their Lal −/− : Soat2 +/+ littermates (Fig. 1A) . There was however, much less of an increase in the hepatic esterified cholesterol (EC) concentration in the double knockouts (Fig. 1B) . This largely accounted for their far lower whole liver cholesterol content compared to that found in their Lal
Whole liver triacylglycerol content was the same in these two particular groups (Fig. 1D ). The most important finding from this experiment was perhaps that, while the absence of SOAT2 in the LAL knockouts substantially blunted EC sequestration in the liver in the period leading up to weaning, it did not completely prevent it. Values are the mean ± SEM of data from 4 to 6 mice in each group except for the double knockouts where n = 9. Different letters denote statistically significant (p < .05) differences as determined by one-way ANOVA. 30.7 ± 1.7. Values are the mean ± SEM of data from 6 to 9 mice at 52 days of age, and from 4 to 6 mice at 100 days. Different letters denote statistically significant (p < .05) differences as determined by two-way ANOVA with genotype and age as variables.
the same four genotypes defined in Fig. 1 but at 52 and 100 days of age (males), and at 52 and 120 days in females (Figs. 2-4 ). In the males, the liver mass in the Lal −/− : Soat2 +/+ mice increased from 2.5 ± 0.1 g at 52 days to 4.4 ± 0.2 g at 100 days ( Fig. 2A) . In their 100-day old Lal −/ − : Soat2 −/− littermates, the liver weight was just 2.3 ± 0.2 g. As illustrated in Fig. 2B , the genotypic differences in hepatic EC concentrations at both 52 and 100 days were even more pronounced than the differences in liver mass. At both of these age points, the double knockout mice had hepatic EC concentrations that were only 26 and 35%, respectively, of those in their Lal (Fig. 2D ) only because liver mass was so much less in the double knockouts ( Fig. 2A) .
The findings for the livers in the females at 52 and 120 days (Fig. 3 ) parallel those for the males. In the double knockout females at these two age points, the liver mass was 61% and 48%, respectively, of that in their Lal −/− : Soat2 +/+ littermates. In assessing the impact of SOAT2
deletion on their levels of hepatic EC sequestration (Fig. 3B) , it should first be noted that in the Lal 
Soat2
−/− females and males, the hepatic EC concentrations were 17.7 ± 1.8 and 14.6 ± 0.7 mg/g, respectively. Thus, in relative terms, the impact of SOAT2 deletion in reducing hepatic EC sequestration did not vary with gender. The data for the small intestine in the aging females ( Fig. 3C and D) are particularly striking. At 120 days, the expansion of intestinal mass seen in the Lal −/− : Soat2 +/+ mice was not evident in their counterparts lacking SOAT2 (Fig. 3C) . Over the period from 52 to 120 days, the intestinal EC concentration in the Lal : Soat2 −/− littermates, the corresponding increase was from 1.3 ± 0.2 to just 2.2 ± 0.2 mg/g (Fig. 3D) . Taken together, the data in Figs. 2 and 3 point to SOAT2 driven EC formation as being a major contributor to the massive expansion of the pool of sequestered EC in the livers and small intestines of this mouse model for CESD.
Hepatic and intestinal unesterified cholesterol concentrations were affected differently by the elimination of SOAT2 function in LAL-deficient mice
Although for tissue cholesterol levels the focus was on the magnitude of the EC fraction, comparatively minor but interesting shifts in hepatic and intestinal unesterified cholesterol concentrations also were found, as illustrated for the 120-day old female mice in Table 1 . In the liver, the UC level did not change in the face of SOAT2 deficiency alone but it increased 3.3-fold in the mice deficient in LAL only. This increment was less pronounced in the DKO mice. For the small intestine, loss of either SOAT2 or LAL resulted in a modest but significant rise in the UC level which increased even more when both proteins were absent. 
Soat2
−/− mice, the increments in the activity of both enzymes were blunted to the extent that the values at 100 days were not statistically different from that at 52 days. Comparable findings are seen for both enzymes in the female mice at 52 and 120 days of age ( Fig. 4C and D) . The conclusion from these transaminase data is strongly supported by the additional finding that, in the livers of the 52-day old male mice, the relative mRNA expression levels for an array of markers of inflammation and macrophage presence including Soat1 (Fig. 5A) , Mip1α 5 to 7 mice at 52 days, and 6 mice in each group at 120 days. Different letters denote statistically significant (p < .05) differences as determined by two-way ANOVA with genotype and age as variables.
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( Fig. 5B) , CD11c (Fig. 5C ) and Tnfα (Fig. 5D ) were all much lower in the Lal −/− : Soat2 −/− mice than their Lal −/− : Soat2 +/+ littermates. Although there are many similarities in cholesterol metabolism between humans with CESD and LAL-deficient mice, the extent to which the latter develop the dyslipidemia seen in CESD patients [40] varies largely with their strain background [22, 32, 41] . The mixed background 52-day old male Lal −/− : Soat2 +/+ mice in the present studies were not hypercholesterolemic (Fig. 6A) , and this was also true of their 100-day old male counterparts (data not shown). The total cholesterol content of the plasma compartment in most animal models, and indeed humans, ordinarily constitutes a small proportion of the entire body cholesterol pool [1] . Hence, the whole body cholesterol content data in the 52-day old male mice ( littermates are not incongruous with the lack of change in the plasma cholesterol concentration in these same mice. From the liver weight and cholesterol concentration data for the 52-day old male mice ( Fig. 2) , it can be calculated that 87.9% of the difference in whole body cholesterol content for the Lal −/− : Soat2 −/− and Lal
Markedly lower whole body cholesterol content in the Lal
−/−
: Soat2 +/+ mice is attributable to the difference in whole liver cholesterol content, with nearly all of this reflecting the decisively lower levels of EC sequestration in the double knockouts.
Discussion
Before evaluating the findings for the Lal −/− : Soat2 −/− mice, two general points about the features of the CESD model we used to generate the double knockouts warrant comment. The first relates specifically to their tissue EC measurements, particularly for the liver, and how these compare to the limited data that are available for humans with CESD. In any model where there is such a marked increase in liver mass, genotypic differences in tissue lipid levels are often best defined by expressing the data on both a mg per gram wet tissue weight, and a whole organ basis. An autopsy report for a 57-year old female with CESD gave the hepatic EC concentration as 44.1 mg/g, with a total liver mass of 1880 g [42] . For normal subjects, an hepatic EC concentration of 0.74 mg/g was noted.
In an earlier case report for a younger adult in males were derived from the same groups of mice as described in Fig. 2 . The corresponding data for the females (panels C and D) were from the same groups described in Fig. 3 . Values are the mean ± SEM of data for the same numbers of mice reported in those respective figures. Different letters denote statistically significant (p < .05) differences as determined by two-way ANOVA with genotype and age as variables. Data are from the same 120-day old female mice described in Fig. 3 . Values are the mean ± SEM of data from 6 mice per group. Different letters denote statistically significant (p < .05) differences as determined by one-way ANOVA using Tukey's multiple comparison test.
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with CESD, the EC concentration in liver was 94.6 mg/g [43] . In the present study, the hepatic EC levels in the 100-day old male Lal : Soat2 +/+ female mice at 120 days it was almost 19%. Irrespective, in both the CESD patient and mouse model, the pool of sequestered EC in the liver can reach several hundred fold more than it is in normal controls. The addition to this figure of all the EC entrapped in extrahepatic tissues reveals how massive the whole body EC pool can become in the aging CESD patient or animal model. The second point centers on the hepatic unesterified cholesterol (UC) concentration which rises with LAL deficiency in both humans and the mouse model. In humans [42, 44] , and the Lal −/− : Soat2 +/+ mice (Table 1) , this elevation is 2-3-fold. The significance and cause of this is unknown but it may be partly a technical artifact in that the amount of EC is so great in LAL deficiency the hydrolysis of even a very small proportion of the EC during processing of the liver and subsequent analytical steps could account for some of this increase in UC concentrations. This has been shown to occur when the liver tissue is initially placed in liquid nitrogen, a step avoided in the current studies [33] . It was essential to look also at intestinal UC and EC levels because the enterocytes, like hepatocytes, are the location of SOAT2 esterifying activity. However, direct comparison of the absolute unesterified, esterified, or total cholesterol concentrations in the liver and small intestine is not valid because the rate of LDL-cholesterol clearance in the small intestine is far below that in the liver [45] , and also because of the continual sloughing of cells from the mucosal surface [46] . Taking these points into consideration, the data for the small intestine in Table 1 show a different impact of LAL and of SOAT2 deficiency alone, and in combination, compared to that seen in the liver. In previous studies with SOAT2-deficient mice, a clear increase in the intestinal total cholesterol concentration was found, with all of this being in the UC fraction [34] . This was seen here in the Lal comparable marginal rise in the intestinal UC level also occurred in the mice deficient in only LAL. It was not surprising that the UC concentration in the Lal −/− : Soat2 −/− mice was higher than in any other group. These differences in UC levels are nevertheless trivial compared to the profound effect that SOAT2 deficiency had on blunting the substantial EC sequestration in the small intestine caused by LAL deficiency (Fig. 3D) . Our initial interest in the LAL-deficient mouse model was to use it in comparative studies with a model for Niemann-Pick C1 (NPC1) disease [47] . It was surprising that, at the time, there were no published data on the impact of selectively deleting either LCAT, SOAT1 or SOAT2 in the LAL-deficient mouse given that knockouts for each of these proteins had been developed [13, 14, 48, 49] . Detailed histological studies of the liver and small intestine in aging LAL-deficient mice by Du et al. [22] revealed a clear presence of proliferating macrophages in these organs and in other tissues, implying that SOAT1, the main cholesterol esterifying enzyme in macrophages, was a contributor to the expanding tissue EC content, especially in the liver and small intestine. Nevertheless, we chose to initially generate the Lal −/− : Soat2 −/− model first, partly because we were already using SOAT2-deficient mice in other studies [34] , but moreover because of the key role that SOAT2 plays in producing atherogenic lipoproteins in the small intestine and liver [11] . Such lipoproteins, including chylomicron remnants, LDL, and VLDL remnants carry most of the EC that becomes sequestered in the E/L compartment of many different cell types with LAL dysfunction. While we recognize that there is a limited literature suggesting that hepatic SOAT2 activity in the mouse may be much higher than it is in humans or certain non-human primates [10] , this does not mean that over an extended period of time the suppression of SOAT2 would have only a minimal impact on EC sequestration rates in the livers of humans with LAL dysfunction. Two particular findings from the current studies warrant discussion. The first relates to the hepatic EC concentrations in the Lal at 120 days reinforced the conclusions reached from the data for the males. Thus, in this particular mouse model of CESD, elimination of SOAT2 has a profound and sustained beneficial impact in reducing hepatic EC sequestration. The basis for this is likely two fold. On the one hand, diminished SOAT2-facilitated EC formation in enterocytes would give rise to a reduced level of chylomicron EC reaching the liver. On the other, the loss of SOAT2 -driven EC formation in hepatocytes presumably leads to less EC present in nascent VLDL and ultimately in LDL particles that are eventually cleared by the liver [10, 50] . The next finding of significance was that the elimination of SOAT2 did not diminish the level of hepatic triacylglycerol sequestration. This was not unexpected in that the benefit of this strategy resides in reducing the amount EC that will eventually become entrapped in the liver and other organs. This is where enzyme replacement therapy is different because it restores the normal processing of both EC and triacylglycerol within the E/L compartment resulting in a clear reduction in the tissue levels of both lipids over time. What is particularly noteworthy about the current result is that, despite triacylglycerol remaining elevated in the Lal −/− : Soat2 −/− mice, their ALT and AST activities and their hepatic mRNA expression levels for several markers of inflammation, including SOAT1, fell in line with the precipitous fall in EC levels. Together, these findings point to the entrapment of EC generated via SOAT2 as a major cause of tissue damage and disease progression in this mouse model. While the development of LAL -deficient mice with selective deletion of either hepatic or intestinal SOAT2 should further define the role of this source of EC in driving disease in LAL deficiency, there is probably a more compelling need to quantify tissue EC and UC levels in the LAL:SOAT1 double knockout model. The overriding question raised by these findings for the Lal −/− : Soat2 −/− model centers on their potential relevance to the management of CESD, especially now that an ERT is available. Underlying this question is the lack of information on how different organ systems handle all the UC that is released from the E/L compartment in various cell types once the replacement LAL begins hydrolyzing the vast pool of EC and triacylglycerol. In Niemann-Pick C disease, where defects in the lysosomal cholesterol transporters NPC2 or NPC1 cause the sequestration of UC in all cells, treatment with 2-hydroxypropyl-β-cyclodextrin leads to the release of this UC, a compensatory suppression of cholesterol synthesis and an increased rate of cholesterol esterification [51] . Thus, with ERT for LAL deficiency, it is conceivable that there is reesterification of some of the newly released UC, especially via SOAT2 in hepatocytes and enterocytes. Preventing this by concurrent treatment with a SOAT2-selective inhibitor might maximize the benefits of ERT [32, 52] . The potential utility of combining small molecule therapy and ERT in the management of LAL deficiency has been recently discussed by Aguisanda et al. [53] .
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